Market Overview

Piper Jaffray Raises PT on ViroPharma to $31

Piper Jaffray has raised the price target on ViroPharma (NASDAQ: VPHM) from $25 to $31 and maintains its Overweight rating.

Posted-In: Piper JaffrayPrice Target Analyst Ratings

 

Most Popular

Related Articles (VPHM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free